This study demonstrates the 25(OH)-vitamin D//3, in an initial dose of 100 mu g/day for 2 weeks followed by 100 mu g qod, is effective in treating the hypocalcemia of patients on maintenance hemodialysis. There was one episode of mild hypercalcemia noted, and no significant rise in serum phosphorus in any patient studied. There is evidence in the literature that 25(OH)-vitamin D//3 is converted into both 1,25,(OH)2-vitamin D//3 and 24,25,(OH)2-vitamin D//3 in patients on maintenance hemodialysis, indicating that there are potential advantages of using 25(OH)-vitamin D//3 over 1,25,(OH)2-vitamin D//3 alone in these patients.
|Original language||English (US)|
|Number of pages||4|
|Publication status||Published - Jul 1987|
ASJC Scopus subject areas